Related Party

Based on its stock ownership in the Company, MD Anderson Cancer Center meets the criteria to be deemed a related party of Bio-Path Holdings. For the quarters ending September 30, 2014 and 2013, MD Anderson related party research and development expense was $16,235 and $15,000, respectively. MD Anderson related party research and development expense for the quarter ending September 30, 2014 was comprised of $1,235 in current patent maintenance fees for the License Agreement and $15,000 for MD Anderson clinical trial hospital expense. Accrued expense related party for MD Anderson was $67,050 for clinical trial hospital costs for the clinical trial and accrued license payments related party of $50,000 for past patent expenses (See Notes 4., 5. and 6.). MD Anderson related party research and development expense for the quarter ending September 30, 2013 was comprised of $15,000 for MD Anderson clinical trial hospital expense. As of December 31, 2013, accrued expense related party consisted of $52,050 for MD Anderson clinical trial hospital costs and $100,000 in accrued license payments payable due to the related party for past patent expenses and for the annual license maintenance fee for the License Agreement. See Notes 5 and 6.